<DOC>
	<DOCNO>NCT00867932</DOCNO>
	<brief_summary>The purpose study determine appropriate dose regimen eculizumab pediatric and/or adolescent patient paroxysmal nocturnal hemoglobinuria ( PNH ) .</brief_summary>
	<brief_title>Eculizumab Pharmacokinetics/Pharmacodynamics Study Pediatric/Adolescent PNH Subjects</brief_title>
	<detailed_description>This open label , multicenter study eculizumab administer intravenously ( IV ) approximately 6 8 pediatric adolescent patient age 2-17 year PNH . Planned duration treatment 12 week .</detailed_description>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Subjects 217 year ; Diagnosis PNH ; subject â‰¥ 5 % glycosylphosphatidylinositol ( GPI ) deficient red blood cell granulocytes confirm flow cytometry ; subject must show evidence hemolytic anemia document lactate dehydrogenase ( LDH ) great upper limit normal least one transfusion past two year anemia anemia relate symptom ; Written Informed Consent parent/guardian ; Negative pregnancy Test Women Child Bearing Potential ; Sexually active female must document reliable medically approve method birth control ; Patient must vaccinate N. meningitidis , S. Pneumoniae H. Influenzae least 14 day prior study drug initiation receive antibiotic 14 day vaccination ; Prior eculizumab treatment ; Presence suspicion active bacterial infection ; Participation another concurrent clinical trial ; History meningococcal/pneumococcal/gonococcal disease ; Pregnant , breast feeding intend conceive study include safety follow visit ; Any condition could increase patient risk confound outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Paroxysmal Nocturnal Hemoglobinuria ( PNH )</keyword>
</DOC>